Literature DB >> 21960419

Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011.

K Walenta1, J M Sinning, C Werner, M Böhm.   

Abstract

This article provides information and commentaries on trials which were presented at the Hotline and Clinical Trial Update Sessions during the Late Breaking Clinical Trial Sessions European Society of Cardiology Congress, held in Paris, France, from 27th to 31st August 2011. This article gives an overview on a number of novel clinical trials in the field of cardiovascular medicine, which were presented. The data have been presented by leading experts in the accordant field with relevant positions in the trials. Unpublished reports should be considered as preliminary data as the analysis may change in the final publications. The comprehensive summaries have been generated from the oral presentation and the webcasts of the European Society of Cardiology, similar as previously reported (Lenski et al. in Clin Res Cardiol Off J Ger Card Soc 99: 679-692, 2010) and should provide the readers with the most comprehensive information of relevant publications. The data were presented by leading experts in the field with relevant positions in the trials.

Mesh:

Year:  2011        PMID: 21960419     DOI: 10.1007/s00392-011-0370-8

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  39 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy.

Authors:  Kenneth A Ellenbogen; Michael R Gold; Timothy E Meyer; Ignacio Fernndez Lozano; Suneet Mittal; Alan D Waggoner; Bernd Lemke; Jagmeet P Singh; Francis G Spinale; Jennifer E Van Eyk; Jeffrey Whitehill; Stanislav Weiner; Maninder Bedi; Joshua Rapkin; Kenneth M Stein
Journal:  Circulation       Date:  2010-11-15       Impact factor: 29.690

3.  The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.

Authors:  Peter S Sever; Choon L Chang; Ajay K Gupta; Andrew Whitehouse; Neil R Poulter
Journal:  Eur Heart J       Date:  2011-08-28       Impact factor: 29.983

4.  Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.

Authors:  C Michael Gibson; Jessica L Mega; Paul Burton; Shinya Goto; Freek Verheugt; Christoph Bode; Alexei Plotnikov; Xiang Sun; Nancy Cook-Bruns; Eugene Braunwald
Journal:  Am Heart J       Date:  2011-05       Impact factor: 4.749

5.  NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation.

Authors: 
Journal:  Am J Kidney Dis       Date:  1997-09       Impact factor: 8.860

6.  Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Authors:  Renato D Lopes; John H Alexander; Sana M Al-Khatib; Jack Ansell; Raphael Diaz; J Donald Easton; Bernard J Gersh; Christopher B Granger; Michael Hanna; John Horowitz; Elaine M Hylek; John J V McMurray; Freek W A Verheugt; Lars Wallentin
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

7.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

8.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

Authors:  Rikke Sørensen; Morten L Hansen; Steen Z Abildstrom; Anders Hvelplund; Charlotte Andersson; Casper Jørgensen; Jan K Madsen; Peter R Hansen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

9.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

10.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

View more
  2 in total

1.  The effect of placebo adherence on reducing cardiovascular mortality: a meta-analysis.

Authors:  Zhao Yue; Cheng Cai; Yang Ai-Fang; Tang Feng-Min; Chen Li; Wang Bin
Journal:  Clin Res Cardiol       Date:  2013-11-22       Impact factor: 5.460

Review 2.  Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more.

Authors:  Christian Ukena; Michael Böhm; Stephan H Schirmer
Journal:  Clin Res Cardiol       Date:  2012-10-12       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.